Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Neuropharmacology. 2009 Jul 9;58(1):88–101. doi: 10.1016/j.neuropharm.2009.06.040

Figure 10. Effects of AVP on the drug expression session on experimental subjects.

Figure 10

Figure 9 shows ambulatory distance traveled within the first 30 minutes of the drug expression session. Experimental subjects injected with AVP 4-9 at 1ng dose traveled greater ambulatory than MC 1ng, 15 ng and vehicle subjects (***, p<0.001). AVP 4-9 at a 15ng dose traveled a greater ambulatory distance than MC 1ng, MC 15ng and vehicle subjects (###, p<0.001). MC at 15ng dose traveled a greater ambulatory distance than MC 1ng dose subjects (ΔΔΔ, p<0.001). Vehicle treated subjects traveled a greater ambulatory distance than MC 1ng subjects (+++, p<0.001). No significant difference was found between AVP 4-9 1ng and 15ng and between MC 15ng and vehicle (p>0.05).